HYBRID EVENT: You can participate in person at Boston, Massachusetts, USA or Virtually from your home or work.

4th Edition of Global Conference on

Addiction Medicine, Behavioral Health and Psychiatry

October 19-21, 2023 | Boston, Massachusetts, USA

GAB 2022

Elizabeth Dale Gilley

Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2022 - Elizabeth Dale Gilley
The Elle Foundation, United States
Title : Precision genomic addiction medicine as a frontline modality as a function of inducing “dopamine homeostasis” in reward deficiency syndrome (RDS): The future is now


Globally we are facing a serious pandemic of uncontrollable addictive seeking behaviors. The opioid crisis in America is just one important facet of this worldwide dilemma. The unfortunate fact is that in the United States 100,000 people prematurely died from opioid induced overdoses in 2021. Clinically providing opioids for opioid abuse reduces harm, it does not actually treat the underlying causes of this unwanted behavior. It is appreciated that one issue is linked to genetic polymorphisms tied to reward genes that constitute the well-characterized brain reward circuitry. In 1995 Blum’s group coined the term Reward Deficiency, Syndrome (RDS) as an umbrella term to help define the known common neurochemical overlap between substance and non-substance addictive behaviors. This construct has  received some mixed reviews but is continually  emerging as an acceptable psychological based disorder having both genetic polymorphic antecedents as well as known epigenetic insults. Currently, there are 213 articles listed in PubMed using the term RDS and “Reward Deficiency” with 1,406 listed (12/14/21). Understanding the potential impact of this construct may have on the addiction medicine field, the purpose of this perspective may provide the primary care physician and others with evidence related to RDS and its scientific basis. Moreover, we also highlight  a case whereby RDS science was utilized to successfully treat a Substance Use Disorder (SUD) treatment resistant patient.  A RDS treatment plan developed by  one of us (EG), using Genetic Addiction Risk Severity (GARS) analysis, assessed neurogenetic challenge, for appropriate design of temporary pharmaceutical and long term nutraceutical intervention. As such we describe the RDS Solution Focused Brief Therapy (RDS-SFBT) and the RDS Severity of Symptoms Scale (SOS) which could provide the clinician with a viable tool for achieving neurological balance, allowing the patient to achieve self-efficacy, self-actualization and thrive.

What will audience learn from your presentation?

  • Audience will be introduced to Reward Deficiency Syndrome Solution which include Genetic Addiction Risk Score Testing to determine phenotype and appropriate neutraceutical amino acid therapy.
  • The presentation introduces the new RDS paradigm, another frame through which to view addictive behavioral expressions which self-medicate dopamine deficiency challenge.
  • RDS Solution Focused Brief Therapy is explained.  A personalized  RDS Severity of Symptom (RDS SOS!) self-measurement test scale is introduced. 
  • This case study report contributes novel application for personalizing comprehensive holistic treatment to address those neurogenetic issues which have previously remained untreated.
  • This case study example of precision genomic addiction medicine is a model for the current transition of the treatment of Reward Deficiency Syndrome as a frontline modality to address RDS over the lifespan, not just in regards to addictive behavioral expression.


Elizabeth Dale Gilley, graduated from Wake Forest University, in 1983 with a Bachelor of Science degree in Business Administration. She founded The Elle Foundation, Dallas, TX, in 1995, initiating the Award of Excellence within the addiction recovery industry in 2000.  She went back to school in her 50’s,  graduated Magna Cum Laude with her Masters in Applied General Psychology (2017) and Post Masters Certificate in Addictions (2019) from NorthCentral University.   She is currently a doctoral student at NorthCentral University, with a 4.0 GPA, studying the philosophy of psychology of addictions, gearing up for her own research in electromagnetic healing frequencies to help achieve dopamine homeostasis. She has published consistently in peer-reviewed doctoral journals for the past six years.